Revvity Inc.

RVTY Healthcare Diagnostics & Research

Revvity Inc.’s revenue for fiscal 2025 (year ended December 2025) was $2.9 billion, up 3.67% from fiscal 2024.

Revenue
+4.29%
EPS
+2.17%
Free cash flow
+27.0%
Total debt
−18.1%

Quarter to September 2026, against a year earlier

150.97 8.46 −5.31%
Market cap
$16.8B
P/E
71.9×
Fwd P/E
66.2×
Dividend yield
0.19%
F-score
6/9
Altman Z
2.49
Beneish M
−2.45
Dividend safety
80/100

Revvity Inc. (RVTY) EBITDA

Alert me on EBITDA

Revvity Inc.'s EBITDA for fiscal 2025 was $766.5M, unchanged from fiscal 2024. Over the twelve months to 30 June 2026 it was $775.8M. Over the past ten years it has ranged from $365.1M (fiscal 2015) to $1.6B (fiscal 2021); the current reading is higher than 64% of that period. Revvity Inc. ranks 12th of 49 Diagnostics & Research companies by EBITDA.

EBITDA, annual

Embed this chart

Annual newest first

Period EBITDA Change
FY2025 $766.5M (1.81%)
FY2024 $780.7M 5.54%
FY2023 $739.7M (39.48%)
FY2022 $1.2B (24.08%)
FY2021 $1.6B 49.89%
FY2020 $1.1B 78.60%
FY2019 $601.4M 14.11%
FY2018 $527.1M 28.75%
FY2017 $409.4M 3.10%
FY2016 $397.1M 8.77%

Quarterly newest first

Period EBITDA Change
Jun 2026 $192.7M 5.81%
Mar 2026 $182.1M (15.63%)
Dec 2025 $215.8M 16.54%
Sep 2025 $185.2M (4.91%)
42 more quarters

Against its own ten years

Low $365.1M High $1.6B
Ten-year median $739.7M
Current reading's percentile 64

EBITDA against peers

What EBITDA is

EBITDA shows what a company earns from its operations before interest, taxes and the non-cash charges for depreciation and amortization.

Reported line item

The full definition of EBITDA →

More on RVTY